PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002586-36-IT

Enrollment

Registered

2005-07-22

Start date

2005-07-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PANCREAS TUMOR TREATMENT MedDRA version: 6.1 Level: PT Classification code 10033609

Interventions

Trade Name: CISPLATINO TEVA*IV 1FL10MG Pharmaceutical Form: Solution for infusion INN or Proposed INN: Cisplatin CAS Number: 15663-27-1 Concentration unit: mg milligram(s) Concentration type: equal Co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026